三阴性乳腺癌Cox回归临床预测模型的构建与验证：基于SEER数据库

来源期刊：广州医药 | 457-468 发布时间：2025-05-07 收稿时间：2025/11/13 18:54:04 阅读量：37

作者：: 殷雨来,

何晓阳,

夏琳,

张晓宇,

关键词：: 三阴性乳腺癌 SEER Nomogram图预测模型预后; triple-negative breast cancer SEER Nomogram predictive modeling prognosis

DOI：: 10.20223/j.cnki.1000-8535.2025.04.005

收稿时间：: 2024-05-20
修订日期：
接收日期：
引用总数：: 0

目的基于SEER数据库分析三阴性乳腺癌（TNBC）的预后,并建立Cox回归临床预测模型且进行内部验证。方法使用SEER*Stat软件（8.4.2版）筛选2010—2015年诊断为TNBC的病例,进行单因素和Cox多因素回归以及向后逐步回归分析,明确与生存相关的独立危险因素,构建预测TNBC患者3年和5年癌症特异生存（CSS）率的Nomogram图,并用受试者工作特征曲线,Harrell’s一致性指数,临床预测模型校准曲线以及决策曲线对该模型进行评估及内部验证,以评估该模型的临床预测效能。结果共筛选出符合纳入标准的TNBC患者5 564例,按照7∶3的比例随机拆分为训练集（n=3 894）和验证集（n=1 670）。通过单因素,多因素分析显示TNM分期、放射治疗、化学治疗以及手术和其他治疗的先后顺序是与TNBC患者CSS显著相关的独立危险因素（P<0.05）。利用上述预后相关因素建立Nomogram图模型。训练集的C-index为0.731（95%CI：0.712~0.749）,验证集的C-index为0.719（95%CI：0.688~0.749）,训练集和验证集3年和5年生存ROC曲线的曲线下面积均>0.7,区分度较好,且校准曲线拟合良好。结论 TNM分期、放射治疗、化学治疗以及手术和其他治疗的先后顺序是TNBC的独立预后因素,基于此建立的Nomogram图临床预测模型区分度、准确度以及临床适用性较好,能较好地预测TNBC患者的生存预后。

Objective To analyze the prognosis of triple negative breast cancer（TNBC）based on the SEER database,and to establish a Cox regression clinical prediction model with internal validation．Methods Cases diagnosed with TNBC from 2010 to 2015 were screened using SEER*Stat software（version 8.4.2）,and univariate and Cox multifactorial regression as well as backward stepwise regression analyses were performed to identify the independent risk factors associated with survival,and to construct a clinical prediction model for predicting the three- and five-year cancer specific survival（CSV）of TNBC patients．Survival（CSS）rates of TNBC patients at 3 and 5 years,and the model was evaluated and internally validated using the ROC curve,Harrell’s consistency index（C-index）,clinical prediction model calibration curve,and decision-making curve（DCA curve）to assess the predictive efficacy of the model for clinical prediction．Results A total of 5 564 TNBC patients meeting the inclusion criteria were screened and randomly split into a training set（n=3 894）and a validation set（n=1 670）according to a 7∶3 ratio．By univariate,multivariate analysis showed that T-stage,N-stage,M-stage,radiotherapy,chemotherapy,and the sequence of surgery and other treatments were independent risk factors significantly associated with CSS in TNBC patients．The above prognostic-related factors were utilized to build a Nomogram plot model．The C-index was 0.731（95%CI：0.712-0.749）for the training set and 0.719（95%CI：0.688-0.749）for the validation set,and the areas under the curves of the 3- and 5-year survival ROC curves of both the training and validation sets were >0.7,which was a good differentiation,and the calibration curves were well-fitted．Conclusions T-stage,N-stage,M-stage,radiotherapy,chemotherapy,and the sequence of surgery and other treatments are independent prognostic factors for TNBC,and the Nomogram clinical prediction model based on this has good differentiation,accuracy,and clinical utility,and can better predict the survival prognosis of TNBC patients．

1、 WU S Y,XU Y,CHEN L,et al.Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC:Concept exploration and biomarker analysis in the FUTURE-C-Plus trial[J].Mol Cancer,2022,21(1):84.

2、 HAN Y,LIU D,LI L.PD-1/PD-L1 pathway:Current researches in cancer[J].Am J Cancer,2020,10(3):727-742.

3、 CHEN F,CHEN N,GAO Y,et al.Clinical progress of PD-1/L1 inhibitors in breast cancer immunotherapy[J].Front Oncol,2022(11):724424.

4、 SCHMID P,CORTES J,DENT R.Pembrolizumab in early triple-negative breast cancer[J].N Engl J Med,2022,386(18):1771-1772.

5、 RIZZO A,CUSMAI A,ACQUAFREDDA S,et al.KEYNOTE-522,IMpassion031 and GeparNUEVO:Changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer[J].Future Oncol,2022,18(18):2301-2309.

6、 MIN Y,LIU X,HU D,et al.Risk factors,prognostic factors,and nomogram for distant metastasis in breast cancer patients without lymph node metastasis[J].Front Endocrinol(Lausanne),2021(12):771226.

7、 SZMIT S,FILIPIAK K J,LITWINIUK M,et al.Liposomal doxorubicin in patients with breast cancer and concomitant cardiovascular diseases - interdisciplinary expert opinion[J].Kardiol Pol,2016,74(9):1031-1036.

8、 WU B B,LEUNG K T,POON E N.Mitochondrial-targeted therapy for doxorubicin-induced cardiotoxicity[J].Int J Mol Sci,2022,23(3):1912.

9、 ANDREOU C,MATSAKAS A.Current insights into cellular senescence and myotoxicity induced by doxorubicin:The role of exercise and growth factors[J].Int J Sports Med,2022,43(13):1084-1096.

10、 XIA L Y,XU W Y,ZHAO Y.Effect of postmastectomy radiotherapy on T1-2N1M0 triple-negative breast cancer[J].PLoS One,2022,17(6):e0270528.

11、 FAN Y,WANG Y,HE L,et al.Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival[J].ESMO Open,2021,6(4):100232.

12、 HUANG X,LUO Z,LIANG W,et al.Survival nomogram for young breast cancer patients based on the SEER database and an external validation cohort[J].Ann Surg Oncol,2022,29(9):5772-5781.

13、颜娇,叶入裴,杨琴,等.不同亚型乳腺癌新辅助化疗后Ki-67表达变化与乳腺癌疗效及预后的相关性[J].诊断病理学杂志,2022,29(11):1001-1004.

14、许关麟,李建文,黄胜超,等.那不勒斯评分预测乳腺癌患者预后的价值[J].现代医院,2024,24(1):53-58.

15、殷雨来,李雪,何晓阳,等.体质量指数和4种女性特征性癌症的因果关系:一项两样本孟德尔随机化研究[J].中华肥胖与代谢病电子杂志,2023,9(4):253-260.

16、来保勇,吕灵艳,赵静,等.10种口服中成药联合化疗治疗乳腺癌的网状Meta分析[J].中草药,2021,52(21):6609-6624.

17、黄雅静,吴昊,陈彦,等.基于SEER数据库的炎性乳腺癌生存预测风险模型的建立与验证[J].现代肿瘤医学,2022,30(6):1023-1027.

18、曲南坤,梁爽,孔启超,等.基于SEER数据库建立三阴性乳腺癌预后预测模型列线图[J].重庆医学,2021,50(20):3457-3462,3468.

19、 GUHA A,FRADLEY M G,DENT S F,et al.Incidence,risk factors,and mortality of atrial fibrillation in breast cancer:A SEER-Medicare analysis[J].Eur Heart J,2022,43(4):300-312.

20、叶晔,费伟强,冯冠.SEER数据库中晚期三阴性乳腺癌的危险因素及预后分析[J].广州医药,2021,52(1):26-34.

21、 LIN Y Y,GAO H F,YANG X,et al.Neoadjuvant therapy in triple-negative breast cancer:A systematic review and network meta-analysis[J].Breast,2022(66):126-135.

22、 XIN Y,SHEN G,ZHENG Y,et al.Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer:A systematic review and meta-analysis[J].BMC Cancer,2021,21(1):1261.

23、 CUI X,ZHU H,HUANG J.Nomogram for predicting lymph node involvement in triple-negative breast cancer[J].Front Oncol,2020(10):608334.

24、 CUI X,SONG D,LI X.Construction and validation of nomograms predicting survival in triple-negative breast cancer patients of childbearing age[J].Front Oncol,2021(10):636549.

25、 CERBELLI B,PERNAZZA A,BOTTICELLI A,et al.PD-L1 expression in TNBC:A predictive biomarker of response to neoadjuvant chemotherapy?[J].Biomed Res Int,2017(2017):1750925.